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Abstract: We report on the enhanced optical transmittance in the NIR wavelength range (900
to 2400 nm) offered by a transparent Yttria-stabilized zirconia (YSZ) implant coupled with
optical clearing agents (OCAs). The enhancement in optical access to the brain is evaluated upon
comparing ex-vivo transmittance measurements of mice native skull and the YSZ cranial implant
with scalp and OCAs. An increase in transmittance of up to 50% and attenuation lengths of up to
2.4 mm (i.e., a five-fold increase in light penetration) are obtained with the YSZ implant and
the OCAs. The use of this ceramic implant and the biocompatible optical clearing agents offer
attractive features for NIR optical techniques for brain theranostics.
© 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
1. Introduction
The brain is protected by different tissue layers, each of them having different optical properties
(e.g., refractive index contrast, scattering and absorption); hence, the analysis of the spectral
features provide information about these different layers [1]. Furthermore, it has been shown that
physiological changes in the different head tissues produce variations in their optical properties
thereby changing the spectral features of the transmitted and reflected light [2]. Compared to
visible light, some spectral regions in the Near Infrared (NIR) spectral range (800 to 2500 nm)
offers advantages such as reduced scattering and absorption as well as a deeper penetration
depth in tissue media [2–4]. Because of these features, some spectral windows within the
NIR wavelength range have shown promising results for brain studies, including deep imaging,
diagnostics and therapeutic applications in brain diseases [5–8].
Different optically transparent windows for head tissues have been identified within the NIR
spectral range. These wavelength windows avoid light attenuation by the tissue due to water
absorption peaks located at 1450 nm and 1940 nm [1,9,10]. The first windowNIR-I (∼ 700−1000
nm), or conventional window, has been well characterized and studied for most tissues, including
brain and other soft tissues [1]. Two additional optical windows have been also identified:
NIR-II (∼ 1000 − 1350 nm) and NIR -III, or short -wave infrared SWIR, (∼ 1550 − 1870 nm);
the latter spectral region has shown to provide maximum light penetration for some kinds of
tissues [7, 11, 12]. More recently, a fourth optical window, SWIR-II (∼ 2100 − 2300 nm) has
allowed for improved optical studies of the brain and for deep brain imaging, particularly when
compared to the NIR -II window [8]. All of these spectral regions have been explored for many
biophotonic applications, although the NIR windows have particularly shown excellent potential
for noninvasive through-skull in vivo brain imaging and spectroscopy [6, 7, 11, 13]. Nonetheless,
it is always desirable to reduce the highly scattering cranial bone over the cortex, which hinders
the observation of optical signals deriving from deeper tissues and reduce the light penetration
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Reduction of the scattering from the skull has been addressed in animal models by craniotomy
[14–16], using a thinned-skull cranial physical window [17,18] or by polishing and reinforcing
a thinned skull piece [19]. Other approaches include optical clearing of the skull [20–22], or
replacement of a portion of the skull with a physical transparent window made from glass or
PDMS [23–25]. All of these are powerful research techniques, but not adequate for translation
into human applications that may require permanent cranial implants. While skull thinning and
polishing techniques affect the required protection for the brain, glass-based physical windows have
a very low toughness (KIC = 0.7− 0.9MPa ·m 12 ) [26] increasing the potentiality of catastrophic
failure by fracture. Similarly, the effects of skull optical clearing agents for long-term use on
human skull is still unknown. A number of biomedical considerations including biocompatibility,
mechanical strength, and ageing performance must be considered for a physical window intended
for eventual clinical applications. Conventional cranial prosthesis including titanium, alumina,
and acrylic [27], do not provide the desired combination of transparency and toughness required
for clinically-viable transparent cranial implants. Other materials such as sapphire have been
also proposed as implants owing to its broadband transparency and toughness thereby providing
optical access to the brain [28]. We have recently also introduced a transparent nanocrystalline
yttria-stabilized-zirconia cranial implant material showing suitable mechanical strength and
biocompatibility sought for a clinically-viable permanent cranial implant for patients [29–31].
Yttria-stabilized zirconia (YSZ) is an attractive alternative due to its relatively high fracture
toughness (KIC ∼ 8MPa · m 12 ) [32], as well as its proven biocompatibility in dental and
orthopedic applications [33–35]. By performing biocompatibility and ageing tests, and through
imaging techniques such as optical coherence tomography [29], ultrasound transmission [36],
multi-wavelength intrinsic optical signal imaging [37] and Laser Speckle Imaging (LSI) [38, 39],
we have demonstrated the feasibility of YSZ implants for chronic cortical imaging in an acute
murine model. Thus, YSZ holds as a promising platform for developing optically transparent
implants with excellent potential for human applications.
In this paper, we report on the enhancement in optical access provided by the transparent YSZ
implant for brain studies in the NIR wavelength range. Because this cranial implant is sought as
a means to obtain optical access for post-operatory and prolonged diagnostics and/or therapy
purposes, scalp scattering must be overcome. In this context, we also evaluate the use of optical
clearing agents (OCAs) in the scalp, particularly their effects on the optical transmittance in
the NIR spectral range. As shown in previous reports, OCAs provide greater optical probing
depths and better contrast, as well as improved light focusing and spatial resolution [40–42].
Therefore, evaluation of the optical features of the YSZ implant together with the use of OCAs in
the NIR spectral range will provide useful information for theranostics applications operating in
this wavelength range (e.g., photobiomodulation [43–45], NIR and fluorescence imaging [3, 46],
cancer diagnosis [47, 48] and brain edema [49]). Hence, we evaluate the enhancement in optical
access to the brain upon comparing ex-vivo transmittance measurements of mice native skull and
the YSZ cranial implant coupled with scalp and OCAs. Using the transmittance data, the total
attenuation lengths were calculated showing that this combination (YSZ and OCAs) offers the
best option for gaining improved optical access to the brain.
2. Samples and methods
2.1. Implant fabrication and preparation
Transparent nanocrystalline 8 mol% YO1.5 yttria-stabilized zirconia (YSZ) implant samples
were produced from a precursor YSZ nanopowder (Tosoh USA, Inc., Grove City, OH, USA)
densified into a transparent bulk ceramic via Current-Activated Pressure-Assisted Densification
(CAPAD) procedure developed by Garay et al. and described extensively previously [50, 51].
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The thickness of the resulting densified YSZ discs were reduced from 1 mm to approximately
450 µm by polishing with 30 µm diamond slurry on an automatic polisher (Pace Technologies,
Tucson, Arizona USA). The samples were then polished with successively finer diamond and
silica slurries ranging from 6 to 0.2 µm. Samples were sectioned into rectangles of approximately
2.6 x 2.1 mm using a diamond lapping saw (WEIYI DTQ-5, Qingdao, China), followed by
sonication in acetone and thorough rinsing in water. The final thickness of the implants was
440±1 µm.
2.2. Scalp and skull samples
The tissue samples were obtained from animals from the University of California, Riverside
(UCR). All experimental procedures and humane care of mice were conducted under a protocol
approved by UCR’s Institutional Animal Care and Use Committee, and in conformance with
the Guide for the Care and Use of Laboratory Animals published by the National Institutes of
Health (NIH Publication No. 85-23, revised 1996). The N=9 8-12 week old C57Bl/6 male mice
(Jackson Laboratory) used in this study were housed under a 12-hour light and 12-hour dark
cycle with ad libitum access to food and water.
2.3. Surgical procedures
Craniectomy surgery was conducted as previously described [39]. Briefly, mice were anesthetized
with isoflurane inhalation (0.2-0.5%), and given ketamine and xylazine (K/X) (80/10 mg/kg, i.p.).
Additional anesthetic was administered as necessary. Hair was removed from the scalp using
clippers and depilatory cream. Mice were then secured into stereotaxic frames to immobilize
the head for surgery. Ophthalmic ointment was placed over the eyes, and the surgical site was
sterilized with alternating application of betadine and 70% EtOH (3 times). A sagittal incision
was made to the left of the midline, and the scalp excised to expose the skull. Periosteum was
removed from the skull, and a craniectomy was performed with a surgical drill and carbide burr
to remove a square section of skull over the right parietal lobe, with dimensions slightly larger
than the implant (2.6 x 2.6 mm).
2.4. Optical clearing
A mixture of two biocompatible agents, PEG-400 (PEG) and Propylene Glycol (PG) (Fisher
Scientific, California, US), were used as scattering reducer and penetration enhancer, respectively,
at a volume ratio of 9:1 [52, 53]. The OCA was prepared and topically applied at room
temperature. A thin layer of the OCAwas applied on the sample and remained for 50 minutes [52].
Characterization experiments were performed before and immediately after applying the OCA;
the increase in transmittance for each tissue used in the samples was monitored every minute
over a 50-minute period. For our experimental conditions, the maxima in transmittance were
achieved within 50 minutes.
2.5. Tissue characterization
Optical transmittance measurements of the different samples used in this study were obtained
through optical spectrometry in the NIR. The setup used to obtain the transmittance spectra
incorporates two multimode optical fibers (P400-2-VIS-NIR, Ocean Optics, FL) attached to
individual fiber holders including VIS-NIR collimating lenses (MP-74-UV, Ocean Optics, FL,
with focal length f = 10mm, lens diameter D = 5mm and NA = D/2 f = 0.4). As depicted in
Fig. 1, the holders were attached to a mechanical rail allowing to adjust the separation between
the fibers and to allocate a sample holder. After the sample is fixed, the fiber holders were tightly
joined together to mitigate detrimental effects from ambient light and back reflections. The light
source used for these measurements was a visible-NIR source (HL2000 FHSA, Ocean Optics,
FL) launched into one of the optical fibers. The beam exiting the launching fiber then traverses
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the sample and is collected by the other fiber, which is connected to a solid-state spectrometer
(NIRQUEST 520, Ocean Optics, FL) to obtain the optical transmission spectra. Spectra were
acquired averaging 10 measurements, with an integration time of 300 ms, in the 900-2400 nm
wavelength range.
Fig. 1. Collimated transmittance measurements setup. The inset shows the housing for
fixing the sample, i.e., the fiber holders with the VIS-NIR collimating lenses. As seen in the
inset, the samples are placed between coverslips (see text for further details).
For all the measurements, the collimated transmittance (T(λ)) was calculated as the ratio of
light transmitted through the sample to the total incident light, i.e.:
T(λ) = S(λ) − D
I(λ) − D (1)
where λ is the wavelength, S is the measured spectral intensity, I is the total light incident and D
represents the reference reading under dark conditions (i.e., no light impinging on the sample).
Basic models of light propagation in biological tissues are described in terms of radiation
transport in a random inhomogeneous media, which includes ballistic and diffuse light [2,5,8,54].
However, when using a collimated beam, and in the case of thin samples with large absorption
coefficients and relatively small light scattering, the ballistic part plays a dominant role and
the diffusive part is negligible [2, 8, 54]. We further consider that the ballistic photons in the
scattering samples are governed by the Beer-Lambert law. Hence, for analyzing the influence
of the sample thickness z in the spectral transmittance, the total attenuation length (lt (λ)) was
calculated as [2, 5, 8, 54]:
lt (λ) = z−ln(T(λ)) (2)
Note that the attenuation length takes into account the sample thickness and therefore provides
a better insight of the light penetration through the samples. In particular, for our experiments,
the thicknesses of the samples are: 440 ± 1µm, 159 ± 1µm and 710 ± 20µm for the YSZ implant,
the mice skull and scalp, respectively. Hence, the YSZ implant is 2.5 times thicker than the mice
skull.
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2.6. Experimental method
The experimental procedure for measuring the ballistic transmittance through the different tissues
and the implant was similar to those reported previously for spectroscopic measurements on soft
tissue [5, 8, 54]. Transmittance measurements were obtained for three sets of samples arranged
as the different scenarios illustrated in Fig. 2. Spectra were obtained first for the skull and
subsequently for the stacked array formed by the scalp placed on top of the skull. The OCAs
were then applied on the scalp and the spectral transmittance was acquired once again. This set
of measurements were also performed using the YSZ implant instead of the skull. The stacking
arrangement used for this measurements allowed for evaluating the effects of each layer on the
spectral features of the sample. This further allows for comparing the spectral features of the skull
and the YSZ implant under similar conditions. Excised full thickness scalp and forehead cranial
bone were rinsed briefly in saline solution to remove the excess blood and their thicknesses
were measured before placing them in the stacked samples. These were finally placed between
two glass microscope coverslips to obtain the transmittance spectra. The same procedure was
followed for the YSZ implant. For the cleared skin measurements the scalps were topically
exposed to PEG and PG as a scattering reducer and a penetration enhancer, respectively [52, 53].
Fig. 2. Stacked sample arrangement used to obtain the spectral transmittance of: 1) the
native skull and YSZ implant, 2) the scalp on top of the skull and the YSZ implant, 3) optical
cleared (OC) scalp on top of native skull and implant.
3. Results and discussion
Figure 3 shows the transmittance (T(λ)) and the attenuation length (lt (λ)) calculated for the native
skull and the implant. The transmittance measurements (Fig. 3(a)) show that the YSZ implant is
more transparent throughout the tested NIR range (900-2400 nm) including all of the optical
windows commonly used for biophotonic applications (i.e., NIR I, NIR II, SWIR I and SWIR II).
This is due to the significant reduction in scattering and absorption when using the YSZ implant.
In terms of relative differences in the optical properties between skull and the implant, the latter
improves the light transmission within the water absorption bands owing to its reduced water
content compared to the native skull (70-75%) [5]. The skull transmittance shows the typical
water absorption bands in the NIR spectral region (1450 nm and 1940 nm [9,10]), while the YSZ
implant shows improved transmittance in these bands. The water absorption peaks apparent in
the implant spectrum are due to traces of the saline solution used for rinsing aiming at obtaining
a fair comparison with the treated tissue samples. A simple calculation of the increase of light
transmitted in these bands using the YSZ implant compared to the native skull yields values
of 47% at 1450 nm and 53% at 1940 nm. The resulting attenuation length shown in Fig. 3(b)
further indicates that, even for the spectral regions with the smallest increase in transmission
(e.g., 3% at 1300 nm), light can penetrate deeper when compared to the native skull. Clearly,
with exception of the second water absorption band, the attenuation length obtained with the
implant increases at least by 1.3 mm, i.e., a four-fold increase in length compared to the skull.
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The spectral regions covered by the water absorption peaks in the NIR have not been explored for
through-skull techniques because of its high water content. Thus, the improved transmission
obtained with the implant opens the possibility to explore new techniques in these wavelength
ranges.
Fig. 3. Transmittance (a) and total attenuation length (b) for the skull and the YSZ implant.
The YSZ implant shows better transmittance throughout the full 900-2400 nm spectral range
compared to the native skull.
The effect of the scalp on the spectra is evident in Fig. 4(a), showing a considerable reduction
in transmission owing to the increased scattering inherent to this tissue [1–3]. As shown in Fig.
4(b), this leads to reduced attenuation lengths for both sample arrangements, i.e., scalp either
on top of the skull or on the YSZ implant. Although for both cases the scalp stacking leads
to a reduction in transmittance of at least 60%, the sample with the implant still provides the
best performance, as confirmed by the attenuation length. Throughout all the spectral range,
the sample formed with the scalp and the YSZ implant provides improved light penetration.
Clearly, the scalp introduces large optical attenuation effects that must be overcome for the
implant to become a convenient means to obtain access for non-invasive optical techniques for
post-operatory diagnostics and/or therapeutic purposes. Hence, we evaluated the use of OCAs as
a technique for improving the transmittance of the samples.
Fig. 4. Transmittance (a) and total attenuation length (b) comparing the stacked samples of
the scalp on top of the skull and on the YSZ implant. The sample with the YSZ implant still
shows better transmittance and improved attenuation length compared to the sample with
the native skull; however, the enhancement is only of 6% in the best case.
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The effects of applying a layer of OCAs on the scalp are evident in Fig. 5; the transmittance
spectra increases by 20% for the sample with the skull, while for the YSZ implant the enhancement
is 40% (Fig. 5(a)). As shown in Fig. 5(b), the attenuation length for both samples increases
accordingly; when compared to the results shown in Fig. 4(b), it is clear that the OCAs effectively
enhance the light penetration yielding larger attenuation lengths throughout the whole NIR range
for both samples. Further comparison of this parameter for the two samples show that the YSZ
provides improved light penetration than attained with the skull (up to 1.8 mm more at 1717 nm).
These results are consistent with previous reports involving OCAs [40–42], and further confirm
that together with the YSZ implant, these biocompatible agents provide attractive features for
optical access to the brain tissue without scalp removal.
Fig. 5. Transmittance (a) and total attenuation length (b) comparing the stacked samples
of the scalp on top of the skull and on the YSZ implant after using the OCAs. The sample
using the YSZ implant with optically cleared scalp (OC scalp) shows an increase of up to
30% in transmittance compared to the sample with the skull.
A better idea of the impact of our results in each of the NIR optical windows can be appreciated
in Fig. 6, showing a summary of the transmittances and attenuation lengths obtained from our
experiments. Comparing all the scenarios, the YSZ implant provides the best option for optical
access, showing the largest transmittance and attenuation length. Although the transmittance
for the YSZ is seemingly comparable to that of the skull for the NIR II and NIR III windows,
the attenuation lengths for the implant are clearly larger than those obtained for the skull (Fig.
6(b)). In fact, for all the windows, the YSZ implant offers improved features and thus better
potential for deeper optical access to the brain tissue, even when using the scalp on top. When
using OCAs to reduce the scattering of the scalp, the YSZ implant offers improved transmittance
and larger attenuation lengths than those observed for the skull. Remarkably, the attenuation
lengths achieved with the OCAs and the YSZ show at least a two-fold increase for the last three
windows (i.e., NIR II, NIR III-SWIR I and SWIR II). Evidently, the optical features offered by
the YSZ implant together with the use of biocompatible agents to reduce scalp scattering pose
new possibilities for probing brain tissue in spectral regions that are commonly discarded owing
to the low penetration depths that can be commonly achieved [5]. Note that these results provide
a direct comparison of the attenuation lengths achieved when replacing the mice skull by the YSZ
implant. It is evident that the transparency of the YSZ implant improves the light penetration, but
the ultimate increase in penetration depth achievable will depend on the scattering features of the
specific bone tissue. Further considerations for the analysis of the spectral transmission should
include the diffuse light component, which is relevant when using thicker and more absorbent
tissue samples (e.g., rat skull [5]).
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Fig. 6. Summary of the registered transmittance (a) and total attenuation length (b) for the
different samples tested in our experiments. Throughout the whole NIR spectral range the
YSZ implant shows enhanced transmittance among all the samples. The use of OCAs on
the scalp effectively increases both, the transmittance and the attenuation length, providing
enhanced light penetration. The most favored optical window for the stacked sample of
optically cleared scalp on top of the YSZ implant is the NIR III (1550-1870 nm, T=67%, lt=
2.86 mm). Error bars represent standard deviation (n=3).
The enhanced transparency of the YSZ implant coupled with the OCAs shows promising
features to facilitate various NIR techniques for theranostics. Photobiomodulation (600-1064
nm) [43–45], NIR and fluorescence imaging (700-1700 nm) [3, 46], as well as some types of
cancer diagnosis (1500-1800 nm) [47,48] and brain edema [49] are a few examples of optical
techniques that could benefit from the improved transmission in NIR spectral range offered by the
YSZ implant. Additionally, any potential adhesion of biochemical agents and/or tissue growth on
the implant (e.g., fibrotic tissue, proteins, cell adhesion) could be potentially monitored over time
using IR reflection techniques [55]. Imaging techniques (e.g., LSI, fluorescence, absorption) that
have been successfully demonstrated to improve with clearing and thinning skull methods [22],
may also benefit from the combination of the OCAs and a transparent YSZ implant.
4. Conclusions
We have evaluated the optical transmission and attenuation length of a novel YSZ-based implant
intended for chronic optical access to the brain performing ex-vivo transmittance measurements.
In addition, the use of OCAs to overcome the low transparency of the scalp was explored together
with the implant. Direct comparison of the YSZ implant with mouse skull in different stacked
arrangements showed that this ceramic material offers enhanced transmission throughout the NIR
spectral range. Furthermore, since OCAs effectively reduce the scattering features of the scalp,
the use of these biocompatible agents together with the YSZ implant provide improved optical
features. In particular, when compared to a typical arrangement comprised of scalp and native
skull, the use of the YSZ implant yields an increase in transmittance of up to 50% and attenuation
lengths of up to 2.4 mm (i.e., a five-fold increase in light penetration). These experimental results
show evidence that the YSZ implant, when used together with the OCAs, offers the best option
for gaining improved optical access to the brain. This novel approach seeks to provide new
opportunities for monitoring brain conditions on a chronically recurring basis, without requiring
repeated craniotomies or scalp removal. Although this study represents only the first step towards
the application of NIR optical techniques for brain theranostics through an implant, it offers a
relevant insight of the opportunities that this transparent material may eventually provide.
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